Recombinant Ephb4-Hsa Fusion Protein
Urinary Bladder Carcinoma
Explore 121 assets in Urinary Bladder Carcinoma →Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02717156CT.gov Multicohort Phase II Trial of sEphB4-HSA+Pembrolizumab in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02767921CT.gov sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Urinary Bladder Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Ephb4-Hsa Fusion Protein (this asset) | University of Southern California | P2 | CCC · 52 |
| Cis-Diamminedichloroplatinum Ii | G1 Therapeutics, Inc. | P3 | BBB |
| Trastuzumab | NKGen Biotech, Inc. | P2 | BB |
| Carboplatin | G1 Therapeutics, Inc. | P3 | BB |
| Vinblastine | University of Southern California | P3 | BB |
| Pembrolizumab | Essen Biotech | P3 | BB |
| Cyclophosphamide | Beijing Biotech | P3 | BB |
| Adriamycin | Toray Industries, Inc | P3 | BB |
| Nivestim | Tulane University Health Sciences Center | P2 | BB |
+42 more in the Urinary Bladder Carcinoma cohort
Other indications for Recombinant Ephb4-Hsa Fusion Protein
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Infiltrating Bladder Urothelial Carcinoma | — | P2/3 | CCC · 55 |
| Non-Small Cell Lung Carcinoma | — | P2 | CCC · 55 |
| Urothelial Carcinoma | — | P2/3 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Ephb4-Hsa Fusion Protein in Urinary Bladder Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-ephb4-hsa-fusion-protein-urinary-bladder-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →